Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten … – GlobeNewswire (press release)
Rare Disease Report |
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten …
GlobeNewswire (press release) NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases … Orphan Drug Designation Granted to Gene Therapy Program for Infantile Batten |
